Kazia and its collaborators are currently running six clinical studies of paxalisib across multiple...
Nanollose set to scale-up production of its tree-free rayon textiles in 2021
Pharmaxis eyes partner funding for LOXL2 inhibitor program; CEO to present at virtual health conference
Zelira Therapeutics accelerates towards commercialisation in 2020
Only registered members can use this feature.
Copyright © Proactive Investors 2021.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.